Fluorinated Estradiol Imaging with Cerianna PET CT: Enhancing Assessment of Estrogen Receptor Positive Breast Cancer
Dr. Robert Bridwell, MD, Co-Founder, Chief Medical Officer, and Head Clinical Architect at Appian 360 introduced fluorinated estradiol imaging for PET CT technology and discussed its use in breast cancer patients with estrogen receptor-positive tumors. He explained that the technology allows for a more comprehensive assessment of the biology across multiple metastatic lesions, rather than relying on a single biopsy site. Dr. Bridwell also discussed the limitations and safety information regarding the diagnostic agent and outlined the diagnostic accuracy of FES technology. He presented case studies to illustrate how FES can change clinical decision-making regarding endocrine therapy, chemotherapy, biopsy, and more. He also discussed factors that impact sensitivity and specificity, caution with medications that impact estrogen receptors, and highlighted that about 30% of patients with primary metastatic breast cancers eventually present with estrogen receptor-negative metastatic lesions.
Breast cancer, with 75% of cases being estrogen receptor-positive, poses challenges in treatment decisions. Endocrine therapy is standard for hormone receptor-positive metastatic breast cancer, but its effectiveness depends on estrogen receptor expression. Fluorinated estradiol imaging (FES) targets estrogen alpha and offers a comprehensive assessment of biology across multiple metastatic lesions, reducing reliance on single biopsies. FES helps clarify estrogen receptor discordance within patients, guiding treatment choices. While FES demonstrates safety and good sensitivity, medication impacting estrogen receptors may affect its efficacy. FES imaging has become crucial in managing recurrent or de novo metastatic breast cancer, enabling thorough evaluations beyond traditional methods
Follow us on social media for the latest updates in B2B!